Evidence map›Paper›PMID 41251166›Full record

ArticleNucleic acids research2026

The IPD-IMGT/HLA database: recent developments in sequence submission.

Dominic J Barker, Richard H L Natarajan, Michael A Cooper, Sebastian J F Hopper, Andrew D Yates, Peter Parham, Steven G E Marsh, James Robinson

Abstract read
In one paragraph

Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Dominic J BarkerAnthony Nolan Research Institute, London, NW3 2QG, United Kingdom.ORCID 0000-0002-3713-2299
Richard H L NatarajanAnthony Nolan Research Institute, London, NW3 2QG, United Kingdom.ORCID 0009-0008-2673-5490
Michael A CooperAnthony Nolan Research Institute, London, NW3 2QG, United Kingdom.
Sebastian J F HopperAnthony Nolan Research Institute, London, NW3 2QG, United Kingdom.ORCID 0009-0003-2233-4167
Andrew D YatesEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton,Cambridge, CB10 1SD, United Kingdom.ORCID 0000-0002-8886-4772
Peter ParhamDepartments of Structural Biology and, Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, United States.
Steven G E MarshUCL Cancer Institute, University College London (UCL), London, WC1E 6DD, United Kingdom.ORCID 0000-0003-2855-4120
James RobinsonAnthony Nolan Research Institute, London, NW3 2QG, United Kingdom.ORCID 0000-0002-2187-5944

Funding

Anthony Nolan Research InstituteBAG DiagnosticsCareDXDKMSEuropean Federation for ImmunogeneticsEuropean Molecular Biology LaboratoriesHistogenetics; Asia-Pacific Histocompatibility and Immunogenetics AssociationLabCorpNMDP #211 392ProTransScisco GeneticsThermo Fisher ScientificWerfen
6 · The paper itself

Abstract

The IPD-IMGT/HLA Database, https://www.ebi.ac.uk/ipd/imgt/hla/, contains >43 000 unique alleles from 47 genes recognized by the WHO Nomenclature Committee for Factors of the HLA System. The HLA system, located within the human major histocompatibility complex on chromosome 6, represents the most polymorphic genes in the human genome and is described as hyperpolymorphic. With the rapid growth of HLA sequencing worldwide, traditional approaches for submitting and accessing data have been challenged. To address these challenges, the IPD-IMGT/HLA Database has expanded its infrastructure by developing Application Programming Interfaces, enabling flexible queries via both a web-based interface and programmatic access. A major advancement is the launch of a new HLA Submission Tool, replacing the previous system after 26 years and >28 000 submissions. The updated tool provides a streamlined user experience, extensive data validation, and automated submissions through an application program interface (API). Importantly, it eliminates the burden of duplicate submissions by offering optional brokering to the European Nucleotide Archive on our submitters' behalf, representing sequences in both databases while ensuring attribution. Together, the new submission tool, submission API, and ENA brokering reduce workload, increase efficiency, and provide ongoing support for the global HLA community.

Indexed as

Databases, GeneticDatabases, Nucleic AcidHLA AntigensAllelesGenome, HumanHumansInternetSoftwareUser-Computer InterfaceHLA Antigens

Identifiers

PMID41251166
PMCPMC12807722

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.